Endovascular therapy for chronic mesenteric ischemia

World J Surg. 2007 Dec;31(12):2416-21. doi: 10.1007/s00268-007-9272-3.

Abstract

Purpose: The purpose of this article is to report on the effectiveness and durability of endovascular therapy for obstructive disease of the superior mesenteric artery and celiac trunk.

Patients and methods: Our retrospective study population included nine patients (five women, four men; mean age 64 years, range 34-83 years) with 15 lesions. The indication for endovascular therapy was chronic mesenteric ischemia. The technical and clinical success rates and the incidence of complications were determined. Follow-up parameters included maintained patency and sustained clinical benefit.

Results: Ten vessels were treated. The primary technical and clinical success rates were both 100% with no perioperative mortality. Major complications occurred in two patients (pseudoaneurysms). During a mean follow-up of 31 +/- 18 months (range 3-60 months), thrombosis occurred in two patients at 1 and 3 months after the procedures, respectively. Thrombosis was successfully treated by catheter-directed intraarterial thrombolysis followed by percutaneous transluminal angioplasty (PTA) (n = 1) or stenting (n = 1). At 2 and 5 years, the primary patency rate was 78%, whereas survival was estimated to be 85% and 68% at 2 and 5 years, respectively. At this follow-up, all patients had obtained relief of symptoms.

Conclusions: Our experience suggests that endovascular treatment for chronic mesenteric arterial obstructive disease is feasible, with a low incidence of complications and acceptable midterm results.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Angioplasty, Balloon*
  • Chronic Disease
  • Disease-Free Survival
  • Feasibility Studies
  • Female
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Ischemia / therapy*
  • Male
  • Mesenteric Artery, Superior
  • Mesentery / blood supply*
  • Middle Aged
  • Recurrence
  • Retrospective Studies
  • Thrombolytic Therapy / methods*
  • Treatment Outcome
  • Urokinase-Type Plasminogen Activator / therapeutic use

Substances

  • Fibrinolytic Agents
  • Urokinase-Type Plasminogen Activator